| 영문 | heparin | 한글 | 헤파린 |
|---|---|---|---|
| 설명 | 혈액 응고를 막는 작용을 하는 다당류의 황산에스테르. 고등동물의 각종 조직에 널리 분포되어 있으며, 수술 후의 혈전증을 막는 데 쓴다. 혈액응고란 지혈의 한 과정으로 섬유소란 물질을 만들어 내는 과정이다. 이 섬유소는 손상된 혈관의 부위에 작용하여 여러 가지 세포들을 얽어 묶는 역할을 하여 결국 손상된 혈관에서 혈액의 소실을 막는다. 이 섬유소는 트롬빈에 의해 섬유소원에서 전환된다. 헤파린이라는 물질은 이 트롬빈을 억제하는 항트롬빈을 활성화하는 물질이다. |
||
| ACD | absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom... |
|---|---|
| SS | disulfide; sacrosciatic; saline soak; saline solution; saliva sample; saliva substitute; Salmonella-... |
| AC | abdominal circumference; abdominal compression; absorption coefficient; abuse case; acetate; acetylc... |
| ACT | achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ... |
| CAC | cardiac-accelerator center; cardiac arrest code; circulating anticoagulant |
| LMW heparin | Low Molecular Weight heparin |
|---|---|
| AC | Anticoagulant |
| LAC | Lupus AntiCoagulant |
| OAC | Oral anticoagulant |
| OAT | Oral anticoagulant therapy |
| anticoagulant | <haematology, pharmacology> Any substance that prevents blood clotting. Those drugs administered for prophylaxis or treatment of thromboembolic disorders are heparin, which inactivates thrombin and several other clotting factors and which must be administered parenterally and the oral anticoagulants (warfarin, dicumarol and congeners) which inhibit the hepatic synthesis of vitamin K dependent clotting factors. Anticoagulant solutions used for the preservation of stored whole blood and blood fractions are acid citrate dextrose (ACD), citrate phosphate dextrose (CPD), citrate phosphate dextrose adenine (cPDA 1) and heparin. Anticoagulants used to prevent clotting of blood specimens for laboratory analysis are heparin and several substances that make calcium ions unavailable to the clotting process, including EDTA (ethylenediaminetetraacetic acid), citrate, oxalate and fluoride. (18 Nov 1997) |
|---|---|
| anticoagulant therapy | The use of anticoagulant drugs to reduce or prevent intravascular or intracardiac clotting. (05 Mar 2000) |
| vascular anticoagulant | <protein> Group of calcium-binding proteins that interact with acidic membrane phospholipids in membranes. They contain 4 or 8 repeats of a 61 amino acid domain that folds into 5 a helices. Also known by several other names (e.g. Lipocortins, endonexins), reflecting the history of their discovery in different contexts. See: lipocortin, endonexin I & II, calpactin, p70 and calelectrin. (18 Nov 1997) |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
| heparin | <drug> Sulphated mucopolysaccharide, found in granules of mast cells, that inhibits the action of thrombin on fibrinogen by potentiating antithrombins, thereby interfering with the blood clotting cascade. Platelet factor IV will neutralise heparin. (18 Nov 1997) |
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| heparin binding growth factor | <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells. Synonym: heparin binding growth factor. Acronym: FGF (18 Nov 1997) |
| heparin cofactor II | <chemical> A sulfated plasma protein with the mw of approximately 66kda. The protein is an inhibitor of thrombin in plasma that is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily. Pharmacological action: serine proteinase inhibitors. Chemical name: Heparin cofactor II (12 Dec 1998) |
| heparin complement | The protein component of heparin in blood. (05 Mar 2000) |
| heparin eliminase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin-glucosamine 3-O-sulfotransferase | <enzyme> Reaction: 3'-phosphoadenylylsulfate + heparin-glucosamine = adenosine 3',5'-bisphosphate + heparin glucosamine 3-o-sulfate Registry number: EC 2.8.2.23 Synonym: glucosaminyl 3-o-sulfotransferase, d-glucosaminyl 3-o-sulfotransferase (26 Jun 1999) |
| heparin, low-molecular-weight | <chemical> Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of haemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. Pharmacological action: anticoagulant, fibrinolytic agent. (12 Dec 1998) |
| heparin lyase | <enzyme> An enzyme of the isomerase class that catalyses the eliminative cleavage of polysaccharides containing 1,4-linked d-glucuronate or l-iduronate residues and 1,4-alpha-linked 2-sulfoamino-2-deoxy-6-sulfo-d-glucose residues to give oligosaccharides with terminal 4-deoxy-alpha-d-gluc-4-enuronosyl groups at their non-reducing ends. Chemical name: heparin lyase Registry number: EC 4.2.2.7 (12 Dec 1998) |
| heparin unit | The quantity of heparin required to keep 1 ml of cat's blood fluid for 24 hr at 0캜; it is equivalent approximately to 0.002 mg of pure heparin. Synonym: Howell unit. (05 Mar 2000) |
| acetic solution | A vinegar. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|